Last 48 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 7.08 | 17.61 | 15.15 | 14.82 | 2.61 | 12.01 | 14.12 | 12.56 | 224.50 | 18.60 | 142.75 | — | — | — | — | — | — | — | — | — | — |
| — | +46.6% | +7.3% | +18.0% | -98.8% | -35.4% | -90.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.58 | 6.54 | 6.81 | 6.56 | 7.17 | 5.11 | 4.33 | 4.47 | 5.54 | 3.94 | 3.60 | 3.59 | 7.16 | 5.09 | 8.33 | 11.36 | 5.40 | 4.78 | 12.63 | 20.28 | 32.26 |
| — | +27.9% | +57.2% | +46.8% | +29.5% | +29.9% | +20.4% | +24.7% | -22.6% | -22.6% | -56.8% | -68.4% | +32.5% | +6.5% | -34.1% | -44.0% | -83.3% | -90.1% | -79.9% | -95.5% | +294.0% | |
| P/B Ratio | 3.93 | 3.33 | 3.69 | 3.59 | 3.81 | 4.11 | 3.62 | 3.19 | 3.51 | 2.75 | 2.26 | 2.01 | 3.42 | 2.83 | 3.52 | 4.00 | 1.52 | 2.52 | 3.36 | 3.91 | 6.30 |
| — | -18.9% | +1.9% | +12.7% | +8.3% | +49.3% | +60.3% | +58.9% | +2.8% | -2.9% | -35.9% | -49.9% | +125.4% | +12.4% | +4.8% | +2.3% | -76.0% | -73.6% | -32.8% | -12.4% | +56.9% | |
| P/FCF | 12.06 | 11.81 | 10.86 | 15.68 | 12.43 | 8.47 | 6.87 | 217.63 | 11.03 | 15.75 | 13.09 | — | 22.65 | — | — | — | 14.89 | — | — | — | — |
| — | +39.5% | +58.1% | -92.8% | +12.7% | -46.3% | -47.5% | — | -51.3% | — | — | — | +52.1% | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 12.02 | 13.69 | 10.49 | 11.18 | 14.48 | 10.89 | 12.44 | 10.56 | 103.51 | 16.80 | 65.72 | — | — | — | — | — | — | — | — | — | — |
| — | +25.7% | -15.7% | +5.8% | -86.0% | -35.2% | -81.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 20.12 | 13.91 | 10.79 | 11.50 | 13.07 | 11.79 | 13.34 | 11.10 | 142.52 | 17.46 | 81.79 | — | — | — | — | — | — | — | — | — | — |
| — | +17.9% | -19.1% | +3.6% | -90.8% | -32.4% | -83.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5% | 90.1% | 92.1% | 91.6% | 89.0% | 88.4% | 89.8% | 86.3% | 90.7% | 91.1% | 84.4% | 84.6% | 88.0% | 87.6% | 96.2% | 98.8% | 95.2% | 95.6% | 94.3% | 98.8% | 97.9% |
| — | +1.9% | +2.5% | +6.2% | -1.9% | -2.9% | +6.4% | +2.0% | +3.1% | +4.0% | -12.3% | -14.4% | -7.5% | -8.4% | +2.0% | -0.0% | -2.8% | -2.7% | -1.1% | +4.3% | -2.1% | |
| Operating Margin | 37.1% | 42.3% | 55.7% | 53.3% | 43.1% | 40.5% | 28.7% | 35.0% | -2.8% | 17.3% | -2.6% | -21.3% | -65.8% | -29.8% | -39.0% | -86.0% | -98.8% | -17.0% | -127.7% | -175.2% | -139.7% |
| — | +4.4% | +94.1% | +52.4% | +1646.2% | +133.6% | +1184.4% | +264.5% | +95.8% | +158.1% | +93.2% | +75.3% | +33.4% | -75.2% | +69.5% | +50.9% | +29.3% | +95.0% | +82.1% | +96.8% | -768.3% | |
| Net Margin | 101.5% | 37.9% | 45.0% | 44.2% | 273.4% | 42.9% | 30.7% | 37.4% | 2.4% | 21.2% | 1.3% | -21.4% | -59.6% | -24.7% | -27.7% | -76.2% | -91.6% | -16.1% | -126.0% | -174.0% | -142.4% |
| — | -11.8% | +46.3% | +18.3% | +11351.8% | +102.8% | +2334.2% | +274.9% | +104.0% | +185.8% | +104.6% | +71.9% | +34.9% | -53.1% | +78.0% | +56.2% | +35.7% | +95.3% | +82.3% | +96.8% | -782.2% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 59.9% | 5.0% | 6.3% | 6.0% | 44.5% | 9.0% | 6.3% | 6.4% | 0.4% | 3.8% | 0.2% | -2.9% | -7.0% | -3.4% | -2.9% | -6.6% | -6.3% | -2.1% | -8.1% | -8.1% | -8.6% |
| — | -44.6% | +0.8% | -6.8% | +11821.1% | +136.0% | +3047.8% | +320.1% | +105.3% | +211.2% | +106.8% | +55.7% | -11.1% | -61.6% | +64.0% | +18.9% | +26.7% | +86.7% | +39.1% | +37.3% | -328.3% | |
| ROA | 44.1% | 3.9% | 4.9% | 4.7% | 33.0% | 6.1% | 4.3% | 4.4% | 0.3% | 2.7% | 0.1% | -2.0% | -4.9% | -2.4% | -2.3% | -5.7% | -5.4% | -1.9% | -7.2% | -7.2% | -7.4% |
| — | -36.0% | +15.5% | +5.3% | +12586.5% | +129.0% | +2977.0% | +319.1% | +105.3% | +209.8% | +106.0% | +64.5% | +10.3% | -31.5% | +68.0% | +20.7% | +26.4% | +86.2% | +38.6% | +37.4% | -322.7% | |
| ROIC | 16.6% | 4.6% | 6.4% | 5.3% | 5.3% | 6.1% | 4.2% | 4.5% | -0.3% | 2.1% | -0.3% | -2.0% | -5.1% | -2.9% | -3.4% | -7.1% | -6.3% | -2.3% | -8.9% | -9.8% | -9.7% |
| — | -25.0% | +53.5% | +19.0% | +1808.2% | +194.9% | +1564.5% | +325.2% | +94.0% | +171.8% | +91.6% | +71.9% | +18.9% | -26.0% | +62.3% | +27.9% | +34.7% | +85.9% | +44.2% | +52.7% | -142.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.09 | 0.10 | 0.12 | 0.13 | 0.21 | 0.24 | 0.22 | 0.21 | 0.23 | 0.24 | 0.25 | 0.26 | 0.24 | 0.26 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| — | -58.3% | -59.7% | -45.6% | -38.8% | -5.6% | +3.5% | -9.7% | -18.6% | -4.8% | -8.6% | +1112.4% | +1194.6% | +1130.0% | +1204.0% | +6.2% | +9.4% | -35.3% | -26.4% | -20.3% | -11.5% | |
| Debt / EBITDA | 0.66 | 1.46 | 1.18 | 1.48 | 1.96 | 2.26 | 3.28 | 2.92 | 24.86 | 5.28 | 25.82 | — | — | — | — | — | — | — | — | — | — |
| — | -35.4% | -64.0% | -49.1% | -92.1% | -57.2% | -87.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.25 | 6.12 | 5.42 | 5.55 | 5.25 | 5.76 | 5.23 | 5.93 | 4.57 | 5.60 | 5.33 | 5.60 | 5.50 | 5.77 | 6.75 | 10.08 | 9.60 | 11.01 | 13.09 | 14.11 | 12.63 |
| — | +6.4% | +3.7% | -6.5% | +14.9% | +2.7% | -1.9% | +5.8% | -17.0% | -2.9% | -21.0% | -44.4% | -42.7% | -47.6% | -48.5% | -28.6% | -24.0% | +25.5% | +9.7% | -19.8% | -3.7% | |
| Quick Ratio | 4.76 | 5.67 | 4.97 | 5.01 | 4.76 | 5.17 | 4.63 | 5.26 | 4.17 | 5.11 | 4.82 | 5.05 | 4.99 | 5.33 | 6.21 | 9.32 | 9.06 | 10.40 | 12.34 | 13.34 | 12.15 |
| — | +9.7% | +7.3% | -4.6% | +14.3% | +1.1% | -4.0% | +4.2% | -16.5% | -4.1% | -22.3% | -45.9% | -44.9% | -48.8% | -49.7% | -30.1% | -25.4% | +26.0% | +8.9% | -20.8% | -4.1% | |
| Interest Coverage | 27.36 | 45.65 | 52.46 | 44.40 | 6.48 | — | 20.84 | 23.82 | 2.02 | 13.26 | 2.23 | -6.80 | -19.16 | -8.39 | -185.68 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AUPH stock.
Aurinia Pharmaceuticals Inc.'s current P/E is 7.1x. The average P/E over the last 4 quarters is 12.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Aurinia Pharmaceuticals Inc.'s current operating margin is 37.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Aurinia Pharmaceuticals Inc.'s business trajectory between earnings reports.